Supplemental material
Journal of Dermatological Treatment
Volume 35, 2024 - Issue 1
Research Article
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Neil J. Kormana Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH, USACorrespondence[email protected]
https://orcid.org/0000-0002-9785-3442View further author information
https://orcid.org/0000-0002-9785-3442View further author information, Richard B. Warrenb Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK;c NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UKhttps://orcid.org/0000-0002-2918-6481View further author information
https://orcid.org/0000-0002-2918-6481View further author information, Jerry Bageld Psoriasis Treatment Center of New Jersey, East Windsor, NJ, USAhttps://orcid.org/0000-0001-5241-0915View further author information
https://orcid.org/0000-0001-5241-0915View further author information, April W. Armstronge University of California Los Angeles, Los Angeles, CA, USAhttps://orcid.org/0000-0003-0064-8707View further author information
https://orcid.org/0000-0003-0064-8707View further author information, Melinda Gooderhamf SKiN Centre for Dermatology, Peterborough, Queen’s University, Kingston, and Probity Medical Research, Waterloo, ON, Canadahttps://orcid.org/0000-0001-8926-0113View further author information
https://orcid.org/0000-0001-8926-0113View further author information, Bruce Stroberg Yale University School of Medicine, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT, USAhttps://orcid.org/0000-0002-8394-2057View further author information
https://orcid.org/0000-0002-8394-2057View further author information, Diamant Thaçih Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germanyhttps://orcid.org/0000-0001-8513-550XView further author information
https://orcid.org/0000-0001-8513-550XView further author information, Akimichi Moritai Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japanhttps://orcid.org/0000-0001-8372-3754View further author information
https://orcid.org/0000-0001-8372-3754View further author information, Shinichi Imafukuj Faculty of Medicine, Fukuoka University Hospital, Fukuoka, Japanhttps://orcid.org/0000-0001-8568-4349View further author information
https://orcid.org/0000-0001-8568-4349View further author information, Peter Foleyk The University of Melbourne, Parkville, St. Vincent’s Hospital Melbourne, Fitzroy, and Probity Medical Research and Skin Health Institute, Carlton, VIC, Australiahttps://orcid.org/0000-0001-5891-5607View further author information
https://orcid.org/0000-0001-5891-5607View further author information, Howard Sofene University of California Los Angeles, Los Angeles, CA, USA;l Dermatology Research Associates, Los Angeles, CA, USAhttps://orcid.org/0000-0001-7789-6915View further author information
https://orcid.org/0000-0001-7789-6915View further author information, Min Zhengm The Second Affiliated Hospital and Zhejiang University School of Medicine, Hangzhou, Chinahttps://orcid.org/0000-0003-4565-844XView further author information
https://orcid.org/0000-0003-4565-844XView further author information, , , & Andrew Blauvelto Oregon Medical Research Center, Portland, OR, USAhttps://orcid.org/0000-0002-2633-985XView further author information
https://orcid.org/0000-0002-2633-985XView further author information show all